Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40794906.
- Also identified by DOI 10.1093/jnci/djaf214 and PMC identifier 12360469.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Molecular Characterization Initiative (MCI), a key effort of the National Cancer Institute's Childhood Cancer Data Initiative (CCDI), was launched in 2022 in collaboration with the Children's Oncology Group (COG) to bring comprehensive genomic and molecular profiling to children, adolescents, and young adults diagnosed with cancer. The MCI provides paired tumor and germline molecular testing, with results returned to clinicians to inform care. Deidentified data are made available to the research community through the CCDI Data Ecosystem to facilitate the discovery of new treatment strategies. This commentary outlines the MCI's development, key accomplishments to date, and its role in laying the foundation for standardized clinical diagnostics in pediatric oncology.
Medical subject headings
- Neoplasms